Listen to the article
A J&J unit is mounting a challenge against what stands as the largest False Claims Act judgment in US history, as it prepares to argue its case before the Third Circuit Court of Appeals in the coming weeks.
Janssen Products, a subsidiary of pharmaceutical giant Johnson & Johnson, is seeking to overturn a staggering $1.6 billion judgment that resulted from allegations that the company improperly promoted antiviral medications for off-label uses not approved by the Food and Drug Administration.
The case, which dates back to 2012, began when two whistleblowers filed suit under the qui tam provisions of the False Claims Act. These provisions allow private citizens to sue on behalf of the government and receive a portion of any recovery. The whistleblowers alleged that Janssen engaged in deceptive marketing practices that misled physicians about appropriate uses for the company’s antiviral drugs, resulting in approximately 160,000 false claims being submitted to federal healthcare programs.
Legal experts are watching the case closely, as Janssen is expected to challenge not just the factual findings but potentially the constitutionality of the whistleblower provisions themselves. The company may argue that allowing private citizens to initiate lawsuits on behalf of the federal government violates constitutional separation of powers principles.
The pharmaceutical industry has long been a target of False Claims Act enforcement, with the Justice Department recovering billions annually from drug companies for alleged marketing violations, kickbacks, and pricing irregularities. This case represents one of the most significant challenges to the government’s enforcement mechanism in recent years.
“This appeal could have far-reaching implications beyond just J&J,” said Sarah Montgomery, a healthcare compliance attorney not involved in the case. “If the Third Circuit were to find constitutional issues with the qui tam provisions, it could fundamentally alter how the government pursues fraud cases against healthcare providers and pharmaceutical companies.”
The original case focused on Janssen’s marketing activities related to its antiviral medications, with allegations that the company promoted uses not supported by clinical evidence or FDA approval. Under federal regulations, physicians may prescribe drugs for off-label uses, but pharmaceutical companies cannot actively market their products for such purposes.
According to court documents, the whistleblowers presented evidence suggesting that Janssen representatives encouraged physicians to prescribe the drugs for patient populations and conditions beyond those specified in the FDA-approved labeling. When these prescriptions were then submitted for reimbursement to Medicare, Medicaid, or other federal healthcare programs, the claims became “false” under the provisions of the act.
The $1.6 billion judgment reflects both the volume of alleged false claims and the statutory penalties and treble damages permitted under the False Claims Act. Such large awards are increasingly common in pharmaceutical cases, though the J&J judgment stands as the current record-holder.
Johnson & Johnson has consistently denied wrongdoing throughout the proceedings. Company representatives have argued that the marketing practices in question fell within appropriate boundaries of scientific exchange and that the company remained committed to providing physicians with accurate information about its products.
The appeal comes at a time when the pharmaceutical industry faces heightened scrutiny from regulators and increased public pressure regarding drug pricing and marketing practices. Major settlements in similar cases have become almost routine, with several leading pharmaceutical firms paying hundreds of millions to resolve False Claims Act allegations in recent years.
The Third Circuit’s eventual ruling could have implications not just for J&J but for how pharmaceutical companies interact with healthcare providers and how the government pursues fraud allegations throughout the healthcare system. A decision is expected sometime in early 2024, though the case could potentially make its way to the Supreme Court depending on the outcome.
Fact Checker
Verify the accuracy of this article using The Disinformation Commission analysis and real-time sources.
10 Comments
The whistleblower provisions seem to be an important tool for uncovering fraudulent behavior, but I can understand J&J’s concerns about their constitutionality. This will be a closely watched case.
Good point. There’s a balance to be struck between incentivizing whistleblowers and protecting the rights of companies. The appeals court will have to weigh these competing interests.
This case highlights the important role of whistleblowers in exposing fraud and holding large corporations accountable. I hope the appeals court upholds the original judgment.
This is a significant case with major implications for the False Claims Act and whistleblower provisions. It will be interesting to see how the appeals court rules on the constitutionality arguments.
Absolutely. The scale of the judgment against J&J’s unit is staggering and highlights the potential legal risks for pharmaceutical companies in off-label marketing.
Deceptive marketing practices in the pharmaceutical industry are deeply concerning. I hope this case sends a strong message that such behavior will not be tolerated.
The scale of the False Claims Act judgment against J&J’s unit is remarkable. It will be fascinating to see how the appeals court rules on the constitutionality arguments.
Indeed. If the judgment is upheld, it could have significant deterrent effects on pharmaceutical marketing practices going forward.
It’s troubling to hear about the alleged deceptive marketing practices around these antiviral drugs. Patients need to be able to trust that pharmaceutical companies are providing accurate information.
I agree. Promoting unapproved uses of medications can lead to serious patient harm. J&J needs to be held accountable if the allegations are proven true.